Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, HC Wainwright Analyst Says

Halozyme Therapeutics (NASDAQ:HALO - Free Report) had its target price raised by HC Wainwright from $70.00 to $72.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company's stock.

Several other equities research analysts also recently weighed in on the company. Piper Sandler increased their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. Wells Fargo & Company decreased their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Finally, JMP Securities increased their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $62.78.

Halozyme Therapeutics Stock Up 0.5 %

HALO traded up $0.31 on Wednesday, reaching $57.75. The company's stock had a trading volume of 1,238,225 shares, compared to its average volume of 1,297,705. The company has a market capitalization of $7.11 billion, a price-to-earnings ratio of 16.84, a P/E/G ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics has a fifty-two week low of $37.73 and a fifty-two week high of $65.53. The stock has a 50 day moving average of $53.26 and a two-hundred day moving average of $54.58. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. As a group, analysts forecast that Halozyme Therapeutics will post 4.72 EPS for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. CBIZ Investment Advisory Services LLC purchased a new position in Halozyme Therapeutics in the fourth quarter worth $29,000. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics in the fourth quarter worth $29,000. Smartleaf Asset Management LLC raised its position in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 197 shares in the last quarter. FSC Wealth Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the third quarter valued at $65,000. Finally, Venturi Wealth Management LLC purchased a new position in shares of Halozyme Therapeutics in the fourth quarter valued at $69,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.